Raiffeisen Bank International AG Raises Holdings in Hologic, Inc. $HOLX

Raiffeisen Bank International AG increased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 33,863.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 232,312 shares of the medical equipment provider’s stock after acquiring an additional 231,628 shares during the quarter. Raiffeisen Bank International AG’s holdings in Hologic were worth $15,600,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Winnow Wealth LLC purchased a new position in shares of Hologic in the third quarter valued at about $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 273 shares in the last quarter. Root Financial Partners LLC bought a new position in shares of Hologic during the third quarter worth $27,000. SJS Investment Consulting Inc. grew its position in shares of Hologic by 341.5% during the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 362 shares in the last quarter. Finally, Loomis Sayles & Co. L P bought a new stake in Hologic in the 2nd quarter worth approximately $33,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HOLX has been the subject of a number of analyst reports. Morgan Stanley increased their price target on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Evercore downgraded Hologic from an “outperform” rating to an “in-line” rating and lowered their price target for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Finally, BNP Paribas Exane downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research note on Friday, November 21st. Two analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Stock Up 0.4%

NASDAQ:HOLX opened at $75.43 on Friday. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $75.47. The stock has a fifty day simple moving average of $74.92 and a 200-day simple moving average of $71.85. The company has a market cap of $16.84 billion, a price-to-earnings ratio of 31.43, a price-to-earnings-growth ratio of 2.24 and a beta of 0.72. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the firm posted $0.87 EPS. The business’s revenue was up 2.5% on a year-over-year basis. Analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.